Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Sadif Analytics (Premium)
$25.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alk Abello A/S Announces Co-Promotion Agreement for GRAZAX with MSD Merck & Co Inc in France


Monday, 10 Sep 2012 02:46am EDT 

Alk Abello A/S announced that it has entered into a co-promotion agreement with MSD, Merck & Co Inc (known as Merck inside the United States and Canada) for GRAZAX in France. GRAZAX is a fast-dissolving, once daily allergy immunotherapy tablet (AIT) for home treatment of grass pollen allergy. GRAZAX works by inducing a protective immune response and offers patients sustained relief of their allergy symptoms. GRAZAX is the only registered disease-modifying allergy immunotherapy tablet. So far, 17 randomized, controlled clinical trials have been completed, and have delivered robust clinical evidence in favor of the treatment. GRAZAX is available as a reimbursed treatment in 16 European countries. ALK's partner in North America, Merck, plans to file a New Drug Application for grass AIT with the United States Food and Drug Administration in 2013. Under the agreement, ALK will book all sales of GRAZAX and MSD will receive a co-promotion fee from ALK which reflects the product's overall sales performance in France. The agreement is expected to have a limited impact on ALK's financial outlook for 2012. ALK therefore continues to expect total revenues of up DKK 2.4 billion and an operating result (EBITDA) in excess of DKK 300 million.